Replies to post #176632 on Biotech Values

[DewDiligence]

French plan to push copycat biotech drugs worries Big Pharma.

Big Pharma can live with European biosimilars that are not interchangeable and have to be marketed as a distinct branded drug.

p.s. New drugs approved by the EMA are entitled to 10 years of marketing exclusivity (and an eleventh year if an second indication is approved).